Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.

Erica L. Mayer; Seth Andrew Wander; Meredith M. Regan; Angela DeMichele; Andres Forero-Torres; Mothaffar F. Rimawi; Cynthia X. Ma; Massimo Cristofanilli; Carey K. Anders; Cynthia Huang Bartlett; Eric P. Winer; Harold J. Burstein

Journal Article

Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.

Mayer E
Wander S
Regan M
et al.

Journal of Clinical Oncology (2018) 36(15_suppl) TPS1104-TPS1104

DOI: 10.1200/jco.2018.36.15_suppl.tps1104

N/ACitations

37Readers

Get full text

Abstract

TPS1104Background: CDK4/6 inhibition (CDK4/6i) has a well-established role in the management of hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (MBC). The addition of a...

Cite

CITATION STYLE

APA

Mayer, E. L., Wander, S. A., Regan, M. M., DeMichele, A., Forero-Torres, A., Rimawi, M. F., … Burstein, H. J. (2018). Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. Journal of Clinical Oncology, 36(15_suppl), TPS1104–TPS1104. https://doi.org/10.1200/jco.2018.36.15_suppl.tps1104

Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.

Abstract

Cite

Register to see more suggestions